Table 2.
Characteristics of patients with flow cytometric analysis.
| Malignant pleural effusion with FACS (n = 69) |
Median (range) | |
|---|---|---|
| OS (days) | 2864-1543) | |
| Age (years) | 72 (41–85) | |
| Sex | Male | 42 (60.9%) |
| Female | 27 (39.1) | |
| Histology | Adenocarcinoma | 57 (82.6%) |
| Squamous cell carcinoma | 4 (5.8%) | |
| Others | 8 (11.6%) | |
| EGFR | yes | 21 (33.3%) |
| no | 42 (66.7%) | |
| ALK | yes | 4 (7.5%) |
| no | 49 (92.5%) | |
| KRAS | yes | 2 (4.7%) |
| no | 41 (95.3%) | |
| Treatment 6 months before tissue procurement | No treatment | 27 (39.1%) |
| Only Chemotherapy | 19 (27.5%) | |
| Only ICI | 4 (5.8%) | |
| Chemotherapy + ICI | 19 (27.5%) |
FACS, fluorescence-activated cell sorting; OS, overall survival; ICI, Immune checkpoint inhibitor.